Relationship of Lipoprotein-Associated Phospholipase A2 Mass and Activity With Incident Vascular Events Among Primary Prevention Patients Allocated to Placebo or to Statin Therapy: An Analysis From the JUPITER Trial

Study Questions:

Does measurement of lipoprotein-associated phospholipase A2 (Lp-PLA2) mass or activity continue to predict risk after low-density lipoprotein cholesterol (LDL-C) reduction by statin therapy?